DOSIS 1/2022

More documents

Info

Pharmacists’ perceptions about knowledge of biologic medicines and their interchangeability and pharmacist-led substitution – A pilot survey of Finnish community pharmacists Senni Kaunisto Chief Pharmaceutical Officer, MSc (Pharm) Pharmaceuticals Pricing Board, Ministry of Social Affairs and Health Affiliation at the time of the study: School of Pharmacy/Social Pharmacy University of Eastern Finland Piia Siitonen University lecturer, PhD (Pharm) School of Pharmacy/Social Pharmacy University of Eastern Finland Hanna Kauppinen Teaching pharmacist, PhD (Pharm) School of Pharmacy/Social Pharmacy University of Eastern Finland Kati Sarnola* Senior Researcher, PhD (Pharm), MSc (Econ) Research at Kela, Social Insurance Institution of Finland Affiliation at the time of the study: Assessment of Pharmacotherapies, Finnish Medicines Agency kati.sarnola@kela.fi *Correspondence Kaunisto S, Siitonen P, Kauppinen H, Sarnola K: Pharmacists’ perceptions about knowledge of biologic medicines and their interchangeability and pharmacist-led substitution – A pilot survey of Finnish community pharmacists. Dosis 38: 74–101, 2022 74 Dosis Vol. 38 1/2022 © Suomen Farmasialiitto ry
Abstract Introduction: Use of biologic medicines is increasing rapidly. Biologic medicines are often considerably more expensive in comparison to traditional synthetic medicines. Yet, the price competition is limited among these medicines. With the introduction of biosimilars and price competition, it is possible to achieve savings – provided that these medicines are made available and adapted into the use. The aim of this study was to explore Finnish pharmacists’ perceptions about biologic medicines and the interchangeability and pharmacist-led substitution of these medicines. Additionally, the knowledge of biologic medicines and confidence to dispense them were explored. Methods: The data was collected with an electronic questionnaire for Finnish community pharmacists in the autumn 2019. The study acted as a pilot study for an international research collaboration project. Results were analysed using frequencies, cross-tabulation, and chi-square test. Key findings: Altogether, 168 questionnaires were analysed. Sixty-one percent of the respondents knew that a biosimilar is a similar copy of a biologic medicine. A quarter (25%) reported feeling sufficiently informed about biosimilars in general. Seventy-four percent of the pharmacists preferred dispensing biosimilars when they have the lowest price. However, 35% of the respondents felt uncomfortable to substitute originator with a biosimilar if pharmacist-led substitution would be possible. Many respondents deemed that substitution on treatment initiation (42%) or during a patient’s treatment course (38%) should be a prescriber decision. Conclusions: According to this study, most Finnish pharmacists have a reasonable level of knowledge about biologic medicines. However, they do not feel sufficiently informed about biosimilars. Pharmacists are not necessarily ready, given their current state of knowledge, to substitute biologic medicines without consulting a physician, and thus additional training is needed. Keywords: biologic medicines, biosimilars, pharmacists, perception, knowledge, survey, interchangeability, substitution Suomen Farmasialiitto ry © 1/2022 Vol. 38 Dosis 75
Page 1 and 2:
Vol. 38 Dosis 1 2022 Farmaseuttinen
Page 3 and 4:
Suomen Farmasialiitto ry © 1/2022
Page 5 and 6:
PÄÄKIRJOITUS Lääkkeiden rahoitu
Page 7 and 8:
lakseni. Tietotarpeet ovat vielä j
Page 9 and 10:
Suomen Farmasialiitto ry © 1/2022
Page 11 and 12:
Tiivistelmä Johdanto: Suomessa hoi
Page 13 and 14:
ydessä järjestettiin raportointi,
Page 15 and 16:
Vuoronvaihto ja raportointi Lääkk
Page 17 and 18:
Lääkehoitoprosessin vaihe Lääke
Page 19 and 20:
Lääkehoitoprosessin vaihe Lääke
Page 21 and 22:
tenkin huomaamatta, mikä johti lä
Page 23 and 24: tietojärjestelmään. Yleensä nä
Page 25 and 26: ammattilaiset voisivat olla mukana
Page 27 and 28: Kirjallisuus Airaksinen M, Hämeen-
Page 29 and 30: Stuijt CCM, Klopotowska JE, Kluft v
Page 31 and 32: LIITE 2: Palvelukodin lääkehoitos
Page 33 and 34: Potilasinformaation varmistaminen T
Page 35 and 36: Tiivistelmä Johdanto: Turvallinen
Page 37 and 38: Aineisto ja menetelmät Tutkimuksen
Page 39 and 40: Taulukko 1. Kyselyyn vastanneiden a
Page 41 and 42: Taulukko 3. Farmaseutin kysymät ky
Page 43 and 44: Tarpeiden ja soveltuvuuden selvitt
Page 45 and 46: duksi neuvonnaksi. Tämä tutkimus
Page 47 and 48: Kirjallisuus Alastalo N, Jyrkkä J,
Page 49 and 50: Mäkelä P, Jokinen L, Airaksinen M
Page 51 and 52: LIITE 1. Kyselylomakkeen itsehoitov
Page 53 and 54: Tiivistelmä Johdanto: Suomalainen
Page 55 and 56: muksen tarkoituksesta, tulosten hy
Page 57 and 58: Taulukko 1. Kyselyyn vastanneiden a
Page 59 and 60: Pohdinta Tämän tutkimuksen mukaan
Page 61 and 62: Lääkärin tai sairaanhoitajan suo
Page 63 and 64: Savossa sijaitsevista apteekeista,
Page 65 and 66: Kirjallisuus Alastalo N, Jyrkkä J,
Page 67 and 68: MacFarlane B, Matthews A, Bergin J:
Page 69 and 70: Liite 1. Kyselylomakkeen valmisteen
Page 71 and 72: 5. Kuinka päädyit valitsemaan tä
Page 73: Suomen Farmasialiitto ry © 1/2022
Page 77 and 78: spective of pharmacists, cost savin
Page 79 and 80: Table 1. Characteristics of the stu
Page 81 and 82: Table 3. Pharmacists’ opinions on
Page 83 and 84: ficiently informed about biosimilar
Page 85 and 86: Tiivistelmä Farmaseuttien ja provi
Page 87 and 88: References Adé A, Bourdon O, Bussi
Page 89 and 90: Biosimilar Medicines: A Survey of P
Page 91 and 92: This next part is about your attitu
Page 93 and 94: This final part of the questionnair
Page 95 and 96: Questionnaire in Finnish: taustatie
Page 97 and 98: Seuraavan osion kysymykset liittyv
Page 99 and 100: Haluaisitko vielä tuoda esiin näk
Page 101 and 102: Weekly Rarely All respondents 75,3
Page 103 and 104: Tiivistelmä Bakteriofagit eli faag
Page 105 and 106: Eliökunta Arkeonit Bakteerit Eukar
Page 107 and 108: Taulukko 1. Bakteriofagien ominaisu
Page 109 and 110: ten hoidossa faagihoito ei vielä s
Page 111 and 112: sesti. Julkaisuissa tulokset ovat l
Page 113 and 114: Osaston lääkäri / muu henkilöku
Page 115 and 116: kirjasto tutkittavaksi. Kansainväl
Page 117 and 118: Kirjallisuus Abedon S: Phage therap
Page 119 and 120: University of Helsinki, Master’s
Page 121 and 122: Abstract Perfluoroalkyl substances
Page 123 and 124: and highly mobile in the atmosphere
Page 125 and 126:
toxic exposure has been reported to
Page 127 and 128:
Table 1. Summary of the development
Page 129 and 130:
Tiivistelmä Katsaus: Perfluoroyhdi
Page 131 and 132:
European Environment Agency (EEA):
Page 133 and 134:
OECD/UNEP: Synthesis paper on per-
Page 135:
Uudistettu Yhteiskunnallinen lääk
show all

DOSIS 1/2022

Create successful ePaper yourself

Delete template?

Save as template?